GO:0015721 bile acid and bile salt transport: Enterohepatic Circulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015721 (bile acid and bile salt transport) describes the directed movement of bile acids and bile salts into, out of, or within cells via transporters or pores.
• Hepatic bile formation depends on coordinated canalicular and basolateral transport of bile acids, which drives bile flow and biliary lipid secretion.
• Key transporters include the canalicular ABCB11 (BSEP) and ABCB4 (MDR3), the basolateral NTCP (SLC10A1) and OATP1B1/1B3, and the intestinal ASBT (SLC10A2).
• The heteromeric organic solute transporter Ostα/β (SLC51A/SLC51B) mediates basolateral efflux of bile acids in ileum, liver, and kidney, and its structure has recently been solved.
• Disruption of bile acid transport causes cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC) and intrahepatic cholestasis of pregnancy.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of bile acid transporter function in hepatocytes and enterocytes.
Description
Bile acid and bile salt transport (GO:0015721) is the biological process by which bile acids and bile salts are moved into, out of, or within cells by transporters or pores. This process is central to bile formation, intestinal fat absorption, and whole-body cholesterol homeostasis, and it depends on the coordinated action of canalicular, basolateral, and intestinal transporters. The directed movement of bile acids is not merely a passive consequence of diffusion; it is an active, energy-dependent process that generates osmotic gradients and drives bile flow. Because bile acids are detergents that can damage membranes, their transport must be tightly regulated and compartmentalized. Researchers study GO:0015721 to understand liver physiology, cholestatic disease mechanisms, and drug-induced liver injury, as well as to develop therapies that target bile acid signaling. The process is also relevant to intestinal disorders, because efficient ileal reabsorption of bile acids is required to maintain the enterohepatic circulation. Recent structural and functional studies have clarified how transporters such as Ostα/β recognize and translocate bile acids, providing a mechanistic framework for interpreting disease mutations. This article summarizes the authoritative QuickGO definition, the main molecular players, the regulatory logic, and the experimental models used to study bile acid and bile salt transport. It is intended for researchers who need a concise, citation-backed overview that can support grant writing, target validation, and CRISPR experimental design.
bile acid and bile salt transport At A Glance
| GO ID | GO:0015721 |
|---|---|
| GO term | bile acid and bile salt transport |
| Ontology | biological_process |
| Synonym | bile acid transport; bile salt transport |
| Definition | The directed movement of bile acid and bile salts into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| Major function | Mediates hepatic bile formation, intestinal bile acid reabsorption, and enterohepatic circulation of bile acids. |
| Key transporters | ABCB11 (BSEP), ABCB4 (MDR3), NTCP (SLC10A1), OATP1B1/1B3, ASBT (SLC10A2), Ostα/β (SLC51A/SLC51B). |
| Cellular locations | Canalicular membrane, basolateral (sinusoidal) membrane, ileal brush-border membrane, and basolateral membrane of enterocytes. |
| Related diseases | Progressive familial intrahepatic cholestasis, intrahepatic cholestasis of pregnancy, bile acid malabsorption, and cholestatic drug injury. |
What Is GO:0015721?
GO:0015721 (bile acid and bile salt transport) is defined by QuickGO as the directed movement of bile acid and bile salts into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. In practice, this includes the uptake of bile acids from portal blood into hepatocytes, their secretion across the canalicular membrane into bile, their reabsorption in the ileum, and their efflux from enterocytes and renal tubular cells back into the circulation. The term is a biological process and is synonymous with bile acid transport and bile salt transport.
Why Is bile acid and bile salt transport Important in Cell Biology?
Bile acid and bile salt transport is essential for liver function, lipid digestion, and cholesterol elimination, and its dysfunction is a direct cause of cholestatic liver disease and bile acid malabsorption. Because bile acids also act as signaling molecules, their transport influences metabolic and inflammatory pathways, making GO:0015721 a high-value process for both mechanistic and therapeutic research.
• Drives bile flow and biliary lipid secretion through osmotic and secretory coupling.
• Maintains enterohepatic circulation, recycling bile acids between liver and intestine.
• Controls cholesterol catabolism and whole-body cholesterol balance.
• Mutations in canalicular transporters cause progressive familial intrahepatic cholestasis.
• Altered ileal transport contributes to bile acid malabsorption and diarrhea.
• Bile acid transporters are targets for drug-induced liver injury and drug-drug interactions.
• Ostα/β provides a basolateral efflux route in liver, intestine, and kidney.
• Transport activity shapes bile acid pool composition and signaling.
• Provides experimental readouts for hepatocyte differentiation and function.
• Enables CRISPR-based causal testing of transporter variants.
What Happens During bile acid and bile salt transport?
Hepatic uptake of bile acids from portal blood
In simple terms: The liver first pulls bile acids out of the blood using transporter proteins on the blood-facing side of hepatocytes.
Hepatocytes take up conjugated bile acids from portal blood primarily via NTCP (SLC10A1) and, to a lesser extent, OATP1B1/1B3, which are expressed on the basolateral (sinusoidal) membrane. This uptake step is sodium-dependent for NTCP and sodium-independent for OATPs, and it ensures efficient first-pass extraction of bile acids returning from the intestine. The driving force and specificity of these transporters determine the composition of the bile acid pool entering the hepatocyte.
Canalicular secretion and bile formation
In simple terms: Inside the liver cell, bile acids are pumped across the canalicular membrane into bile, and this pumping creates the osmotic force that makes bile flow.
Canalicular secretion of bile acids is mediated by the ATP-binding cassette transporter ABCB11 (BSEP), which uses ATP hydrolysis to move bile acids against a concentration gradient. ABCB4 (MDR3) flips phosphatidylcholine into bile, and ABCG5/ABCG8 export cholesterol, together forming biliary lipid secretion. The osmotic activity of secreted bile acids draws water into the canalicular conduit, generating bile flow. This step is rate-limiting for bile formation and is a common target of cholestatic injury.
Intestinal reabsorption of bile acids
In simple terms: In the gut, specialized cells grab bile acids back from the intestine so they can be returned to the liver.
In the ileum, the apical sodium-dependent bile acid transporter ASBT (SLC10A2) mediates uptake of bile acids from the intestinal lumen into enterocytes. Inside the enterocyte, bile acids are bound by ileal bile acid-binding protein (IBABP) and then exported across the basolateral membrane by the heteromeric organic solute transporter Ostα/β (SLC51A/SLC51B). This reabsorption is highly efficient and is the first step of the enterohepatic circulation.
Basolateral efflux and return to the liver
In simple terms: After being taken up, bile acids are released from the other side of the cell back into the blood so they can travel to the liver again.
Ostα/β mediates basolateral efflux of bile acids in ileocytes, hepatocytes, and renal proximal tubular cells, completing the return arm of the enterohepatic circulation. Structural studies of Ostα/β have revealed a unique fold and a mechanism for bile acid transport that explains how conjugated and unconjugated bile acids are recognized. In the liver, basolateral efflux also provides an escape route for bile acids when canalicular secretion is impaired, limiting hepatocellular injury.
Renal handling and alternative excretion
In simple terms: The kidney can also filter and excrete bile acids, providing a backup route when the liver cannot secrete them normally.
The kidney expresses Ostα/β and other transporters that mediate bile acid uptake and efflux in proximal tubules, contributing to urinary excretion of bile acids. Under cholestatic conditions, renal excretion and basolateral efflux become more important for clearing retained bile acids. This alternative route is relevant to the pathophysiology of cholestasis and to the interpretation of bile acid measurements in blood and urine.
Key Genes Involved in GO:0015721 bile acid and bile salt transport
The following genes encode transporters, binding proteins, and enzymes that directly participate in or regulate bile acid and bile salt transport (GO:0015721).
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCB11 (BSEP) | Canalicular ATP-dependent bile acid export | PFIC2 and drug-induced cholestasis; target for transport assays |
| ABCB4 (MDR3) | Canalicular phosphatidylcholine flippase supporting bile formation | PFIC3; biliary lipid secretion studies |
| ABCG5 | Canalicular cholesterol export | Sitosterolemia; reverse cholesterol transport |
| ABCG8 | Canalicular cholesterol export | Sitosterolemia; bile acid synthesis regulation |
| SLC10A1 (NTCP) | Basolateral sodium-dependent bile acid uptake | Hepatocyte bile acid uptake; HBV entry studies |
| SLC10A2 (ASBT) | Apical ileal bile acid uptake | Bile acid malabsorption; enterohepatic circulation |
| SLC51A (Ostα) | Basolateral bile acid efflux subunit | Ostα/β structure and transport mechanism |
| SLC51B (Ostβ) | Basolateral bile acid efflux subunit | Conjugated and unconjugated bile acid transport |
| SLCO1B1 (OATP1B1) | Basolateral sodium-independent bile acid uptake | Drug-drug interactions; cholestasis susceptibility |
| SLCO1B3 (OATP1B3) | Basolateral sodium-independent bile acid uptake | Hepatocyte transport assays |
| NR1H4 (FXR) | Nuclear receptor regulating bile acid transport genes | Feedback control of bile acid pool |
| CYP7A1 | Rate-limiting bile acid synthesis enzyme | Bile acid pool size and transport load |
| CYP8B1 | Bile acid synthesis enzyme determining pool composition | Bile acid species and transport specificity |
| FABP6 (IBABP) | Intracellular ileal bile acid binding | Enterocyte bile acid trafficking |
| SLC27A5 (BAL) | Bile acid-CoA ligase for conjugation | Bile acid conjugation and transport |
| BAAT | Bile acid-CoA:amino acid N-acyltransferase | Conjugation status affecting transport |
| AKR1D1 | Steroid 5β-reductase in bile acid synthesis | Bile acid synthesis defects |
How Is bile acid and bile salt transport Regulated?
Bile acid and bile salt transport is regulated by a negative feedback loop centered on the nuclear receptor FXR (NR1H4), which senses intracellular bile acids and represses CYP7A1 while inducing transporters such as ABCB11 and Ostα/β. This feedback adjusts bile acid synthesis and transport capacity to match the size and composition of the bile acid pool. Hormonal and osmotic signals also modulate bile flow and canalicular secretion, linking transport activity to water movement into the canalicular conduit. In the intestine, FXR activation reduces ASBT expression and induces Ostα/β, limiting bile acid uptake when the pool is expanded. These regulatory mechanisms are important because they determine how cells respond to cholestatic stress and how transporters adapt during disease.
bile acid and bile salt transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCB11 | PFIC2; drug-induced cholestasis | Hepatocyte knockout and point-mutation models |
| ABCB4 | PFIC3; biliary lipid secretion defect | Knockout hepatocyte and transport assays |
| SLC10A2 | Bile acid malabsorption | Enterocyte knockout and uptake assays |
| SLC51A/SLC51B | Ostα/β deficiency; bile acid efflux defect | Knock-in and overexpression models |
| NR1H4 | Altered bile acid pool regulation | Reporter and knockout models |
Progressive familial intrahepatic cholestasis (PFIC)
Mutations in canalicular transporters cause severe cholestatic liver disease. ABCB11 (BSEP) defects underlie PFIC2, and ABCB4 (MDR3) defects cause PFIC3, both of which impair bile acid and phospholipid secretion and lead to bile acid retention. Patient-specific mutations can be modeled in stem cell-derived hepatocytes to study transport defects and potential therapies. These disorders illustrate how a single transport step in GO:0015721 can determine liver injury and outcome.
Intrahepatic cholestasis of pregnancy and drug-induced cholestasis
Hormonal and pharmacological inhibition of bile acid transporters can cause intrahepatic cholestasis of pregnancy and drug-induced liver injury. Variants in ABCB11 and ABCB4, as well as inhibition of NTCP or BSEP by drugs, increase susceptibility to cholestasis. Because bile acid transport is rate-limiting for bile flow, even partial inhibition can produce clinical cholestasis.
Bile acid malabsorption and intestinal disorders
Impaired ileal reabsorption of bile acids, often involving ASBT (SLC10A2) or Ostα/β dysfunction, leads to bile acid malabsorption and chronic diarrhea. Loss of efficient enterohepatic circulation also alters bile acid pool composition and can affect lipid absorption and colonic function. Studying these transporters in enterocyte models helps define how transport defects translate into intestinal symptoms.
Metabolic and cardiovascular links
Bile acid transport intersects with reverse cholesterol transport and bile acid synthesis, which are relevant to atherosclerosis and metabolic disease. Activation of LXR-α and ABCG5/G8 promotes cholesterol efflux and bile acid synthesis, indirectly influencing transport load. These connections make GO:0015721 a process of interest beyond classical cholestasis.
From bile acid and bile salt transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ABCB11 impair canalicular bile acid secretion? | ABCB11 knockout hepatocyte model |
| Does a patient variant in SLC10A1 reduce bile acid uptake? | Point-mutation knock-in in hepatocytes |
| Can Ostα/β overexpression enhance basolateral efflux? | Overexpression model in enterocytes or hepatocytes |
| Where does a tagged transporter localize in polarized cells? | Tagged knock-in with imaging |
| Does FXR regulate a transporter gene in response to bile acids? | Reporter and knockout models |
| Can CRISPR screening identify modifiers of bile acid transport? | Library screening in hepatocyte-like cells |
How to Study the bile acid and bile salt transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled bile acid transport assay | Uptake and efflux rates | Quantifying transporter activity |
| Fluorescent bile acid imaging | Directional transport in live cells | Polarized hepatocyte studies |
| Stem cell-derived hepatocyte model | Human-relevant transport phenotype | Patient mutation modeling |
| Cryo-EM structure determination | Transporter architecture and mechanism | Ostα/β and related transporters |
| RNA-seq / qPCR | Transporter gene expression | Regulation and disease profiling |
| Immunofluorescence | Protein localization | Apical vs basolateral sorting |
| CRISPR knockout | Loss-of-function transport phenotype | Causal gene testing |
| CRISPR library screening | Modifiers of transport | Pathway discovery |
Transport assays in polarized cells
Bile acid transport is commonly measured using radiolabeled or fluorescent bile acid analogs in polarized hepatocyte or enterocyte cultures, allowing separate assessment of apical and basolateral transport. These assays can quantify uptake, efflux, and directionality, which are the defining features of GO:0015721.
Stem cell-derived hepatocyte models
Human stem cell-derived hepatocytes can be engineered to carry patient-specific mutations and then used to model bile acid transport and synthesis defects. This approach links genotype to transport phenotype and enables drug testing in a human-relevant system.
Structural and biochemical analysis of transporters
Cryo-EM and biochemical assays have been used to determine the structure and mechanism of Ostα/β, revealing how bile acids are recognized and translocated. Such studies provide a structural basis for interpreting disease mutations and for designing transport modulators.
Expression and localization profiling
RNA-seq, qPCR, and immunofluorescence are used to profile transporter expression and localization across liver, intestine, and kidney. These methods help determine whether changes in transport capacity arise from altered expression, trafficking, or intrinsic activity.
How CRISPR Can Be Used to Study GO:0015721 bile acid and bile salt transport
Knockout
CRISPR knockout of bile acid transporters such as ABCB11, SLC10A1, or SLC51A in hepatocyte or enterocyte models can establish whether a given transporter is required for a specific transport step. Knockout models are also useful for measuring compensatory changes in other transporters and for testing drug sensitivity.
Point Mutation
Point-mutation knock-in can recreate patient variants in transporters and assess their impact on bile acid transport activity and localization. This approach is particularly valuable for variants of uncertain significance in genes such as ABCB11 or SLC10A1.
Knock-in
Tagged knock-in of transporters enables visualization of localization and trafficking in polarized cells without overexpression artifacts. Knock-in of reporter cassettes can also be used to monitor transporter promoter activity in response to bile acids.
Overexpression
Overexpression of transporters such as Ostα/β or ASBT can enhance bile acid flux and help define rate-limiting steps in the transport pathway. Overexpression models are also useful for testing whether increased transport capacity protects against bile acid toxicity.
How EDITGENE Supports bile acid and bile salt transport Research
Researchers studying bile acid and bile salt transport-related genes often need to determine whether a candidate gene is causally involved in uptake, efflux, or bile formation, and which variants alter transporter function. EDITGENE provides CRISPR-based cell models and screening services that allow such questions to be tested directly in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for bile acid and bile salt transport research.
Frequently Asked Questions About bile acid and bile salt transport
What is GO:0015721?
GO:0015721 is the Gene Ontology term for bile acid and bile salt transport, defined as the directed movement of bile acids and bile salts into, out of, or within a cell, or between cells, by means of a transporter or pore.
What genes are involved in bile acid and bile salt transport?
Key genes include ABCB11, ABCB4, ABCG5, ABCG8, SLC10A1, SLC10A2, SLC51A, SLC51B, SLCO1B1, SLCO1B3, NR1H4, CYP7A1, CYP8B1, FABP6, SLC27A5, and BAAT.
What is the function of bile acid and bile salt transport?
It mediates hepatic bile formation, intestinal bile acid reabsorption, and enterohepatic circulation, and it drives bile flow through osmotic gradients.
Where does bile acid and bile salt transport occur?
It occurs at the canalicular and basolateral membranes of hepatocytes, the apical and basolateral membranes of ileal enterocytes, and in renal proximal tubules.
What diseases are linked to bile acid transport defects?
Defects cause progressive familial intrahepatic cholestasis, intrahepatic cholestasis of pregnancy, drug-induced cholestasis, and bile acid malabsorption.
How is bile acid transport regulated?
It is regulated by FXR-mediated feedback, which adjusts synthesis and transporter expression to match the bile acid pool.
What is the role of Ostα/β in bile acid transport?
Ostα/β is a heteromeric basolateral transporter that mediates bile acid efflux in ileum, liver, and kidney, and its structure has been solved.
How can CRISPR be used to study bile acid transport?
CRISPR knockout, point-mutation, knock-in, and overexpression models can test whether specific transporters or variants are required for bile acid uptake or efflux.
What methods measure bile acid transport?
Radiolabeled and fluorescent transport assays, stem cell-derived hepatocyte models, cryo-EM, RNA-seq, and immunofluorescence are commonly used.
Why is bile acid transport important for cholesterol metabolism?
Bile acid transport is required for cholesterol elimination and is coupled to reverse cholesterol transport and bile acid synthesis.
Conclusion
GO:0015721 (bile acid and bile salt transport) is a central biological process that connects liver bile formation, intestinal reabsorption, and cholesterol homeostasis through a defined set of transporters and regulatory circuits. Understanding its molecular players and regulation is essential for interpreting cholestatic disease mechanisms and for developing targeted therapies. CRISPR-based cell models provide a direct way to test causal roles of transporters and variants in this pathway.
References
- 1. Boyer JL. 2013. Bile formation and secretion.. Compr Physiol 3(3):1035-78 PMID: 23897680
- 2. Javitt NB. 2020. Hepatic bile formation: bile acid transport and water flow into the canalicular conduit.. Am J Physiol Gastrointest Liver Physiol 319(5):G609-G618 PMID: 32935994
- 3. Hayashi H et al.. 2021. Modeling Human Bile Acid Transport and Synthesis in Stem Cell-Derived Hepatocytes with a Patient-Specific Mutation.. Stem Cell Reports 16(2):309-323 PMID: 33450190
- 4. Bahar RJ et al.. 1999. Bile acid transport.. Gastroenterol Clin North Am 28(1):27-58 PMID: 10198777
- 5. Yang X et al.. 2026. Structures of Ostα/β reveal a unique fold and bile acid transport mechanism.. Nature 651(8104):260-267 PMID: 41606328
- 6. Li X et al.. 2025. Qingre Sanjie Formula alleviates atherosclerosis by promoting LXR-α/ABCG5/G8-mediated reverse cholesterol transport and bile acid synthesis.. Phytomedicine 142:156691 PMID: 40286749
- 7. Suga T et al.. 2019. Characterization of conjugated and unconjugated bile acid transport via human organic solute transporter α/β.. Biochim Biophys Acta Biomembr 1861(5):1023-1029 PMID: 30853579
- 8. Shneider BL. 2001. Intestinal bile acid transport: biology, physiology, and pathophysiology.. J Pediatr Gastroenterol Nutr 32(4):407-17 PMID: 11396803
